When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response
- 16 August 2015
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 13 (8) , 1163-1173
Abstract
Multiple myeloma is a plasma cell malignancy with an estimated 26,850 new cases and 11,240 deaths in 2015 in the United States. Two main classes of agents are the mainstays of therapy—proteasome inhibitors (PI) and immunomodulatory drugs (IMiD). Other new targets are emerging rapidly, including monoclonal antibodies and histone deacetylase (HDAC) inhibitors. These therapeutic options have greatly improved overall survival, but currently only 15% to 20% of patients experience long-term progression-free survival or are cured. Therefore, improvement in treatment options is needed. One potential means of improving clinical options is to target resistance mechanisms for current agents. For example, eliminating the cytoprotective heat-shock response that protects myeloma cells from proteasome inhibition may enhance PI-based therapies. The transcription factor heat-shock factor 1 (HSF1) is the master regulator of the heat-shock response. HSF1 is vital in the proteotoxic stress response, and its activation is controlled by posttranslational modifications (PTM). This review details the mechanisms of HSF1 regulation and discusses leveraging that regulation to enhance PI activity. Mol Cancer Res; 13(8); 1163–73. ©2015 AACR.Keywords
This publication has 117 references indexed in Scilit:
- HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human CancersCell, 2012
- Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomibBlood Cancer Journal, 2012
- Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseasesNature Reviews Drug Discovery, 2011
- XPB, a subunit of TFIIH, is a target of the natural product triptolideNature Chemical Biology, 2011
- KRIBB11 Inhibits HSP70 Synthesis through Inhibition of Heat Shock Factor 1 Function by Impairing the Recruitment of Positive Transcription Elongation Factor b to the hsp70 PromoterJournal of Biological Chemistry, 2011
- Heat shock factors: integrators of cell stress, development and lifespanNature Reviews Molecular Cell Biology, 2010
- Guidelines for the nomenclature of the human heat shock proteinsCell Stress and Chaperones, 2008
- Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of CarcinogenesisCell, 2007
- Phosphorylation of serine 230 promotes inducible transcriptional activity of heat shock factor 1The EMBO Journal, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999